Helping You Build Wealth With Honest Research
Since 1996. Try Now

MEMBER'S LOGIN

MEMBER'S LOGINX

     
Invalid Username / Password
   
     
   
     
 
Invalid Captcha
   
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

Indian stock markets trade strong
Mon, 15 Apr 01:30 pm

Led by persistent buying, Indian stock markets are trading strong on the back of favorable inflation data in the post noon trading session. Among the sectoral indices, stocks from the oil and gas and PSU sectors were among the leading gainers, while stocks from IT and consumer durables were the top losers.

BSE-Sensex is up by 155 points and NSE-Nifty is trading up by 57 points. While BSE Mid Cap is trading up by 0.6%, BSE Small Cap index is trading up by 0.7%. The rupee is trading at 54.62 to the US dollar.

As per a leading financial daily, inflation based on Wholesale Price Index (WPI) declined to three-year low of 5.96% in March 2013 as compared to 6.84% in the preceding month and 7.69% in the year-ago month. The inflation figures for March 2013 are also considerably lower than Reserve Bank's projection of 6.8% for the month. The easing in the inflation rate was on account of steep drop in vegetable prices. The inflation in vegetables reached -0.95% in March from 12.11% in the previous month. Consequently inflation in the food articles, with a 14.3% share in WPI basket, dropped to 8.73% in March from 11.38% in February. With inflation cooling off and industrial production remaining sluggish at 0.6% for February, expectations have risen for a rate-cut by RBI in its annual monetary policy on 3rd May.

Most of the domestic pharma stocks are trading in the green with Elder Pharma and Fresenius Kabi Oncology being among the leading gainers. Sun Pharmaceuticals Ltd, has announced that the USFDA (United States Food and Drug Administration) has given two tentative approvals for the generic version of sitagliptin 25mg, 50mg and 100mg tablets and metformin hydrochloride (HCl) 500mg and 1,000 mg extended release tablets. Sitagliptin tablets are therapeutic equivalents of Merck Sharp & Dohme Corporation's Januvia tablets. The drug has branded annual sales of US$ 2.7 bn in the US. Metformin HCl Extended-release tablets, are therapeutic equivalents of Santarus Inc.'s Glumetza tablets. The branded sales of the drug are around US$ 140 m in the US. Both the drugs are indicated to patients suffering from Type II diabetes. The stock of Sun Pharma was trading up by 1%.

For information on how to pick stocks that have the potential to deliver big returns, download our special report now!

View all commentaries | Archives

Read the latest Market Commentary


Equitymaster requests your view! Post a comment on "Indian stock markets trade strong". Click here!

  
ABOUT EQUITYMASTER

Since 1996, Equitymaster has been the source for honest and credible opinions on investing in India. With solid research and in-depth analysis Equitymaster is dedicated towards making its readers- smarter, more confident and richer every day. Here's why hundreds of thousands of readers spread across more than 70 countries Trust Equitymaster.

PREMIUM PRODUCTS
QUICK LINKS
POPULAR TOPICS
TRENDING TOPICS
FREE NEWSLETTERS
EQUITYMASTER SUPPORTS
  • HelpYourNGO
  • You Tube
  • Linkedin
  • Twitter
  • Telegram
  • Google Play

Copyright © Equitymaster Agora Research Private Limited.

Whitelist | Refer | Terms | Privacy | Contact | About | Sitemap

Phone +91-9136015013

Equitymaster Agora Research Private Limited (Research Analyst)
SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.

103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
Telephone: +91-22-61434055. Email: info@equitymaster.com. Website: www.equitymaster.com.
CIN:U74999MH2007PTC175407

Name of the Compliance & Grievance Officer: Ms Sonal Ramachandran
Telephone: +91-22-61434003 | Email: compliance@equitymaster.com

LEGAL DISCLAIMER:
Investment in securities market are subject to market risks. Read all the related documents carefully before investing.
Registration granted by SEBI and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

All rights reserved. Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.

Equitymaster Agora Research Private Limited (Research Analyst) bearing Registration No. INH000000537 (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA, Canada or the European Union countries, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.